Interesting to note Matt Zeller heads up Novartis in Australia and was a speaker on the From Mines to Medicines - Australia Poised for a Radiopharmaceuticals Revolution podcast. I could postulate that Cheryl also from Novartis has been in discussions with him in regards to our radiotheranostics
Matt Zeller
Country President Novartis Australia and New Zealand
Sydney, New South Wales, Australia
AboutAbout
Collaborative, servant leader delivering transformational results across a range of functions, markets, and disease areas. Global experience in strategy and execution combined with passion for developing winning teams and bringing breakthrough innovation to patients.Collaborative, servant leader delivering transformational results across a range of functions, markets, and disease areas. Global experience in strategy and execution combined with passion for developing winning teams and bringing breakthrough innovation to patients.
ActivityActivity
Moving to a new country and learning about the society and environment is always exciting. I see many opportunities to make a difference in the lives of Australian patients and their families, but one company can’t do it alone. Working alongside partners across the healthcare ecosystem will be key at this pivotal time. It was fun to talk with Megan Brodie and MedNews Aust/NZ about some initial impressions and the exciting path ahead.
It was great to speak with Caroline Duell and Dana Bell about the MTPConnect Mines to Medicines discussion paper. Radiopharmaceuticals represent an important opportunity to help improve the lives of Australian patients and South Australia is well positioned to potentially play a leading role. There’s more work to do, but I can’t wait to see where the conversation takes us next
Matt Zeller posted this • 2mo2mo
What a way to end my first week in the Canberra!
Yesterday, Novartis, Australia & New Zealand announced an important partnership with Shane Warne Legacy to bring community-based heart health testing to rural and regional electorates where there is a high prevalence of Cardiovascular Disease (CVD).
I was proud to stand with CEO of Shane Warne Legacy Helen Nolan and the Parliamentary Friends of Rural and Regional Health, Office of Fiona Phillips MP and Dr Anne Webster MP, to share that we’ll be working together to deliver 12-minute, pharmacist-led heart health checks to approximately 2,400 people over 40 testing days in the electorates of Gilmore and Mallee in the coming months. We’re moving beyond medicines to bring preventative heart health testing to people where they are and when they need it.
This was part of an event hosted by Milton Dick MP, where we released a report developed by HTANALYSTS that demonstrates how the new Test, Treat, Track model of care for CVD has the potential not only to improve health outcomes, but also to boost the Australian economy and productivity. Novartis is committed to working in partnership with stakeholders in new ways across the entire healthcare ecosystem in ANZ to make a difference for patients and their families in Australia.
Many thanks to the Minister for Health and Aged Care Mark Butler MP who spoke in support of our efforts and took advantage of the opportunity to have his own CVD risk factors checked by the wonderful team from Wesfarmers Health and SiSU Health Group
It’s clear that we need to do more to more to address the burden of CVD and Novartis is a passionate and willing partner in the fight against Australia’s leading cause of death.
• Managed transformation of ~$500Mn business across 24 countries including Baltics, Albania, Bulgaria, and Ukraine amid conflict. Focused on installing new strategy, building new team & culture, and shifting resources to drive growth• Managed transformation of ~$500Mn business across 24 countries including Baltics, Albania, Bulgaria, and Ukraine amid conflict. Focused on installing new strategy, building new team & culture, and shifting resources to drive growth
• Elected to Boards of American and Swiss Chambers of Commerce & Association of Innovative Pharma Manufacturers
• Realized #1 position in Oncology through data-driven decision making, new access channels, and 1st in region launch of nuclear medicine/radioligand
• Built talent/culture (1st “Top Employer” Award) & 1st-in-country partnerships; 2023 Expat “CEO of the Year” finalist• Elected to Boards of American and Swiss Chambers of Commerce & Association of Innovative Pharma Manufacturers • Realized #1 position in Oncology through data-driven decision making, new access channels, and 1st in region launch of nuclear medicine/radioligand • Built talent/culture (1st “Top Employer” Award) & 1st-in-country partnerships; 2023 Expat “CEO of the Year” finalist
• Managed design/implementation of new global commercial org of large cap biopharma as part of transformation to specialty-based portfolio & cost reduction initiative; focused on global marketing/access & commercial ops functions
• Led redesign of mid-cap pharma's US sales forces using innovative ROI-based customer segmentation & sales force sizing approach; resulted in ~30% sales force reduction and a flexible design with limited business disruption• Managed design/implementation of new global commercial org of large cap biopharma as part of transformation to specialty-based portfolio & cost reduction initiative; focused on global marketing/access & commercial ops functions • Led redesign of mid-cap pharma's US sales forces using innovative ROI-based customer segmentation & sales force sizing approach; resulted in ~30% sales force reduction and a flexible design with limited business disruption
• Led project to define the China branded generics strategy for a leading global biopharma, including portfolio selection framework/criteria and a revised go-to-market model; resulted in significant strategic shift & reinvestment
• Managed China implementation as part of a global reorganization of the structure, design, and strategy of marketing & market access functions within the Emerging Markets business unit of a leading biopharmaceutical company
• Drove global product/pipeline diagnostic for R&D group of leading biopharma & med tech conglomerate including benchmarking & assessment of productivity requirements; resulted in changes to R&D strategy & funding approach• Led project to define the globalization strategy for a leading Chinese biopharma company; focused on market selection, entry options & sequence, portfolio strategy & key product types/technologies, & overall business case/expected return • Led project to define the China branded generics strategy for a leading global biopharma, including portfolio selection framework/criteria and a revised go-to-market model; resulted in significant strategic shift & reinvestment • Managed China implementation as part of a global reorganization of the structure, design, and strategy of marketing & market access functions within the Emerging Markets business unit of a leading biopharmaceutical company • Drove global product/pipeline diagnostic for R&D group of leading biopharma & med tech conglomerate including benchmarking & assessment of productivity requirements; resulted in changes to R&D strategy & funding approach
• Led project to define the globalization strategy for a leading Chinese biopharma company; focused on market selection, entry options & sequence, portfolio strategy & key product types/technologies, & overall business case/expected return
• Led diagnostic & redesign of a large pharma's U.S. women's health care customer facing model; achieved ~$30M in savings through new flexible field structure & designed selling model to account for future portfolio & customer needs
• Supported design and implementation of a global ~$800M profit improvement program for a med tech company, including creation of a revised customer segmentation and go-to-market strategy to enhance sales & service productivity
• Supported a leading biopharma company in the commercial workstream of a post-merger integration of a leading biotech; responsible for managing global Onc/Hematology/Transplant synergy realization & new business design
• Redesigned incentive compensation strategy for leading biopharma and built framework/model for future IC design• Led diagnostic & redesign of a large pharma's U.S. women's health care customer facing model; achieved ~$30M in savings through new flexible field structure & designed selling model to account for future portfolio & customer needs • Supported design and implementation of a global ~$800M profit improvement program for a med tech company, including creation of a revised customer segmentation and go-to-market strategy to enhance sales & service productivity • Supported a leading biopharma company in the commercial workstream of a post-merger integration of a leading biotech; responsible for managing global Onc/Hematology/Transplant synergy realization & new business design • Redesigned incentive compensation strategy for leading biopharma and built framework/model for future IC design
SPL Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
